Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
September 19 2022 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical
company that is developing an entirely new class of cellular
medicines called Red Cell Therapeutics™ for the treatment of cancer
and autoimmune diseases, today announced that Pablo J. Cagnoni,
M.D., president and chief executive officer, will participate in a
fireside chat at the Guggenheim Nantucket Therapeutics Conference
on Thursday, September 29, 2022, at 11:15am EDT.
A live audio webcast will be available within the Investors
& Media section of the Rubius Therapeutics website. An archived
replay will be accessible for 90 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a biopharmaceutical company that is
developing an entirely new class of cellular medicines called Red
Cell Therapeutics™ for the treatment of cancer and autoimmune
diseases. The Company was named among the 2021 Top Places to Work
in Massachusetts by the Boston Globe, and its manufacturing site
was recently named 2022 Best Places to Work in Rhode
Island by Providence Business News. For more information,
visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us
on Facebook.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended, including, without limitation, statements regarding
beliefs about and expectation for the restructuring plan described
in this release, including associated costs, cost savings and
timing, as well as our beliefs about the next generation red blood
cell platform, including that it will potentially improve upon the
existing benefits of the RED PLATFORM, and its potential for
greater efficacy and enhanced versatility. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
release, including, without limitation, risks related to the
substantial doubt about our ability to continue as a going concern
given that we currently do not have adequate financial resources to
fund our forecasted operating costs for at least 12 months; our
ability to execute on and realize the expected benefits of the
restructuring plan described in this release; the amount of debt we
have outstanding and the lender’s rights under our loan facility,
including the lender’s ability to accelerate amounts outstanding
under the loan facility, or exert control over our cash accounts in
connection with certain events of default, including a material
adverse change in our business; our ability to pursue and secure
financing to fund our operations; our ability to maintain our
listing on the Nasdaq Stock Market, particularly in light of our
recently disclosed deficiencies; those risks and uncertainties
related to the development of the our Red Cell Therapeutic product
candidates and their therapeutic potential; risks related to our
ability to execute on our plans and expectations and our analyses
of clinical and preclinical data; and other risks identified in our
filings with the U.S. Securities and Exchange Commission (SEC),
including our Quarterly Report on Form 10-Q for the quarter-ended
June 30, 2022 and subsequent filings with the SEC. We caution you
not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made. We disclaim any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements. Any
forward-looking statements contained in this release represent our
views only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date.
Investor and Media ContactLori Murray, Chief
Corporate Affairs Officer lori.murray@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Apr 2023 to Apr 2024